Since PH1 is caused by the genetic mutations of AGT enzyme, identifications of AGT mutant enzyme activators and GO inhibitors are two potentially therapeutic approaches for small molecule drug development to treat this rare disease. Here, AGT is linked to primary hyperoxaluria type 1.